The DOI matches its Crossref record; 96 of the 96 references it cites were found in a registry or an index.
Children's Oncology Group's 2013 blueprint for research: Neuroblastoma
Abstract
Estimated 5‐year survival rates for patients with non‐high‐risk and high‐risk neuroblastoma are 90% and 50%, respectively. Recent clinical trials have shown excellent outcomes with reduced therapy for non‐high‐risk disease. For patients with high‐risk neuroblastoma treated with chemoradiotherapy, surgery, and stem cell transplantation, the addition of anti‐disialoganglioside (GD2) immunotherapy plus cytokines improves survival. Upcoming trials will study the incorporation of targeted radionuclide therapy prior to myeloablative chemotherapy into high‐risk treatment. Phase 2 trials will investigate druggable target(s) including mTOR inhibition and GD2‐directed therapy in combination with chemotherapy for patients with recurrent neuroblastoma, and ALK inhibition for those with ALK‐aberrant tumors. Pediatr Blood Cancer 2013; 60: 985–993. © 2013 Wiley Periodicals, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chronic Health Conditions in Adult Survivors of Childhood Cancer
Oeffinger, K. C., Mertens, A. C., Sklar, C. A., Kawashima, T., Hudson, M. M., Meadows, A. T., Friedman, D. L., Marina, N., Hobbie, W., Kadan-Lottick, N. S., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmsa060185 · Cited by 3,597
Brodeur, G. M., Pritchard, J., Berthold, F., Carlsen, N. L., Castel, V, Castelberry, R. P., De Bernardi, B., Evans, A. E., Favrot, M., & Hedborg, F. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.8.1466 · Cited by 2,294
Amplification of N- myc in Untreated Human Neuroblastomas Correlates with Advanced Disease Stage
Brodeur, G. M., Seeger, R. C., Schwab, M., Varmus, H. E., & Bishop, J. M. (1984) · Science · doi:10.1126/science.6719137 · Cited by 2,262
Association of Multiple Copies of the N-myc Oncogene with Rapid Progression of Neuroblastomas
Seeger, R. C., Brodeur, G. M., Sather, H., Dalton, A., Siegel, S. E., Wong, K. Y., & Hammond, D. (1985) · New England Journal of Medicine · doi:10.1056/nejm198510313131802 · Cited by 2,010
Recent Advances in Neuroblastoma
Maris, J. M. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0804577 · Cited by 1,983
Self-citationThe International Neuroblastoma Risk Group (INRG) Classification System: An INRG Task Force Report
Cohn, S. L., Pearson, A. D. J., London, W. B., Monclair, T., Ambros, P. F., Brodeur, G. M., Faldum, A., Hero, B., Iehara, T., Machin, D., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.6785 · Cited by 1,910
Self-citationAnti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma
Yu, A. L., Gilman, A. L., Ozkaynak, M. F., London, W. B., Kreissman, S. G., Chen, H. X., Smith, M., Anderson, B., Villablanca, J. G., Matthay, K. K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0911123 · Cited by 1,835
Self-citationIdentification of ALK as a major familial neuroblastoma predisposition gene
Mossé, Y. P., Laudenslager, M., Longo, L., Cole, K. A., Wood, A., Attiyeh, E. F., Laquaglia, M. J., Sennett, R., Lynch, J. E., Perri, P., et al. (2008) · Nature · doi:10.1038/nature07261 · Cited by 1,407
Self-citationEpigenetic protein families: a new frontier for drug discovery
Arrowsmith, C. H., Bountra, C., Fish, P. V., Lee, K., & Schapira, M. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3674 · Cited by 1,327
The International Neuroblastoma Risk Group (INRG) Staging System: An INRG Task Force Report
Monclair, T., Brodeur, G. M., Ambros, P. F., Brisse, H. J., Cecchetto, G., Holmes, K., Kaneko, M., London, W. B., Matthay, K. K., Nuchtern, J. G., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.6876 · Cited by 1,150
Self-citation
Cited by
Revised Neuroblastoma Risk Classification System: A Report From the Children's Oncology Group
Irwin, M. S., Naranjo, A., Zhang, F. F., Cohn, S. L., London, W. B., Gastier-Foster, J. M., Ramirez, N. C., Pfau, R., Reshmi, S., Wagner, E., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.00278 · Cited by 494
Self-citationNeuroblastoma: clinical and biological approach to risk stratification and treatment
Tolbert, V. P., & Matthay, K. K. (2018) · Cell and Tissue Research · doi:10.1007/s00441-018-2821-2 · Cited by 304
Ma, E., Chen, P., Wilkins, H. M., Wang, T., Swerdlow, R. H., & Chen, Q. (2017) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2017.09.008 · Cited by 79
YAP1 Mediates Resistance to MEK1/2 Inhibition in Neuroblastomas with Hyperactivated RAS Signaling
Coggins, G. E., Farrel, A., Rathi, K. S., Hayes, C. M., Scolaro, L., Rokita, J. L., & Maris, J. M. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-1415 · Cited by 66
Self-citation
Metadata
- Authors
- Park, J. R., Bagatell, R., London, W. B., Maris, J. M., Cohn, S. L., Mattay, K. M., Hogarty, M., & on behalf of the COG Neuroblastoma Committee
- Venue
- Pediatric Blood & Cancer
- Publisher
- Wiley
- Published
- 2012-12-19
- Volume
- 60
- Issue
- 6
- Pages
- 985-993
- ISSN
- 1545-5009 (ISSN-L)
- 1545-5017
- OpenAlex
- W2064013031
- Cited by
- 332
- References
- 96
- FWCI
- 9.72
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Children's Oncology Group's 2013 blueprint for research: Neuroblastoma. https://app.cochat.ai/papers/10.1002/pbc.24433
- The paper
- Park, J. R., Bagatell, R., London, W. B., Maris, J. M., Cohn, S. L., Mattay, K. M., Hogarty, M., & on behalf of the COG Neuroblastoma Committee. (2013). Children's Oncology Group's 2013 blueprint for research: Neuroblastoma. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.24433
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
